CeQur Simplicity Wearable Insulin Patch Now Available Nationally with Up to 7 Days of Wear and 1-Unit Dosing: Taking on the Mealtime Insulin Problem

A new CeQur/Harris Poll finds that half (51%) of U.S. adults managing diabetes with mealtime insulin delivered by pen or syringe/vial miss or skip doses.

HORW, Switzerland, Nov. 10, 2026 — CeQur^®, the company dedicated to simplifying mealtime insulin delivery for people living with diabetes, today announced national availability of two enhancements to the CeQur Simplicity™ wearable insulin patch: FDA- cleared wear for up to seven days and a new 1-unit dosing option. Announced in, June 2026, these enhancements expand the device's wear duration and dosing flexibility, giving healthcare professionals additional options to individualize mealtime insulin delivery. With the new clearances, one patch now replaces up to 21 mealtime injections, and 1-unit dosing joins the established 2-unit dosing.

"Mealtime insulin has been delivered essentially the same way for decades, and the data shows that approach isn't working for everyone," said Bradley Paddock, President and Chief Executive Officer of CeQur. "CeQur Simplicity is the first and only mealtime insulin patch that can be worn for up to 7 days. The availability of 7-day wear in two dosing options gives healthcare professionals and their patients an effective alternative to multiple daily injections."

Mealtime insulin decisions often occur in the middle of everyday life – in a restaurant, at work, at a social gathering or at home at the dinner table. In a new CeQur/Harris Poll survey of 409 U.S. adults managing diabetes with mealtime insulin delivered by pen or syringe/vial, 51% reported missing or skipping doses, and 52% said they do not always carry their mealtime insulin supplies when they leave their home. Among respondents who reported missing doses and answered the public-setting question, 70% said they had missed a dose because they were in a public setting.

The strain of managing mealtime insulin extends beyond the injection itself and into other facets of life. The survey found that among all respondents, managing mealtime insulin has affected their:

• Ability to do their job effectively (61%)
• Psychological well-being (54%).
• Daily responsibilities (49%).
• Enjoying time with friends and family (45%).

"Patients who have diabetes live with it 24/7, and injecting insulin multiple times a day impacts their whole life, everything," said Jennifer Goldman, PharmD, CDCES, professor of pharmacy practice at the Massachusetts College of Pharmacy and Health Sciences in Boston and director of cardiometabolic services at Well Life in Peabody, Massachusetts. "People know they're supposed to take their insulin, but life gets in the way. Do I have my pens? Do I have needles? Will there be a clean place to put my things out? Am I going to have to use a public bathroom to inject myself? That's where someone makes a conscious decision and says: I'm just not going to do it."

Mealtime insulin doesn't have to work this way. Instead of packing or carrying it, you wear it. CeQur Simplicity can be worn on the abdomen, upper arm or thigh and hidden under clothing, so it is discreet and goes where the person goes.

There's no pen or supplies to forget, no reason to put the dose off until later. With CeQur Simplicity, mealtime insulin is discreet and always with you. One click delivers the dose.

People with diabetes who take mealtime insulin injections are encouraged to talk with their healthcare professional about CeQur Simplicity. To learn more, visit MyCeQurSimplicity.com.

Survey Methodology

This survey was conducted online within the United States by The Harris Poll on behalf of CeQur from August 10 - 13, 2026, among 409 U.S. adults ages 18 and older managing diabetes with mealtime insulin delivered via pen/syringe/vial. The sampling precision of Harris online polls is measured by using a Bayesian credible interval. For this study, the sample data is accurate to within +/- 6.5 percentage points using a 95% confidence level. This credible interval will be wider among subsets of the surveyed population of interest. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact [email protected].

References

1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.
2. Bergenstal R., et al Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles; Journal of Diabetes Science and Technology 1–7, 2021.

SOURCE CeQur Corporation